2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 65

Genetic Heterogeneity in the Risk of Lupus Nephritis According to Ancestry

Genetics, Genomics and Proteomics - Poster I

9:00AM-11:00AM: Abstract Number: 57

Genetic Polymorphism of IL-1RN Encoding the IL-1 Receptor Antagonist Predicts Radiographic Severity of Symptomatic Knee OA

Genetics, Genomics and Proteomics - Poster I

9:00AM-11:00AM: Abstract Number: 13

Genetic Variants of the Vasoactive Intestinal Peptide (VIP) Gen in Association with Rheumatoid Arthritis Treatment Requirements

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 647

Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 885

Giant Cell Arteritis and Malignancy – More Than Just a Coincidence?

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 878

Giant-Cell Arteritis Related Stroke: A Retrospective Multicentre Case-Control Study

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 438

Glucocorticoid Adverse Effects – the Patient Perspective

Quality Measures and Quality of Care - Poster I

9:00AM-11:00AM: Abstract Number: 288

Glucose Homeostasis Influences the Risk of Incident Knee Osteoarthritis

Osteoarthritis – Clinical Aspects - Poster I

9:00AM-11:00AM: Abstract Number: 584

Glycoprotein VI: A Potential Target for ACPA-Mediated Platelet Activation?

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 629

Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 413

Golimumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 7 Cases and Literature Review

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 519

Greater Fatigue at Baseline and Female Gender Predict Worse Disability in Early RA Despite Treatment to Target: A Comparison of Two Observational Cohort Studies from the United Kingdom

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 555

HAQ Score Is an Independent Predictor of Sustained Remission in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 25

Have Outcomes of Patients with Inflammatory Arthritis Improved in the New Millennium? a Comparison of the 10 Year Outcome in Cohorts Recruited in 1990-4 and 2000-4

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 890

Health-Related Domains of Importance to Patients with Takayasu’s Arteritis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].